

India Equity Institutional Research II

Q₂FY₂5 – Result Update

II 14th Nov 2024

DCX Systems Ltd.

A Quarter Full of Critical Order Wins from leading US Defense Player.. Now Eyes on Execution!

CMP	Target	Potential Upside	Market Cap (INR Mn)	Recommendation	Sector
INR 303	INR 466	54%	INR 33,800	BUY	Electronic- Component


Result Highlights of Q2FY25:

- In tandem with historical trend of seasonality, DCX delivered a muted H1FY25 but slew of order wins was the showstopper in Q2FY25 with a total order worth of INR.30,000 Mn. For the Q2 in specific, higher material cost continued to weigh on margin and resulted into a miss
- Though the gross margin improved for the quarter sequentially but it continues to be under pressure. Similarly, EBITDA margin continues to be in negative territory but it improved on a sequential basis.
- The recent order wins add confidence on the revenue visibility for the near to medium term. However, lack of clarity on the recovery of increased raw material costs and persisting margin pressure have caused us to revise down our EPS estimates for FY25E and FY26E by -34%/-10%. Overall, we continue to hold our conviction on DCX's ability to become a key player in EMS space with huge potential lying ahead in the railway and defence space. Consequently, we retain our P/E multiple of 36x on FY26E EPS and maintain our BUY rating on the counter with the target price of INR 466 (Previously: INR 519).

MARKET DATA

Shares outs (Mn)	111		
Mkt Cap (INR Mn)	33,800		
52 Wk H/L (INR)	452/235		
Volume Avg (3m K)	310		
Face Value (INR)	2		
Bloomberg Code	DCXINDIA IN		

SHARE PRICE PERFORMANCE



MARKET INFO

RESEARCH ANALYST

SENSEX	77,580					
NIFTY	23,533					

KEY FINANCIALS

Particulars (INR Million)	FY22	FY23	FY24	FY25E	FY26E
Revenue from Operations	11,023	12,536	14,236	16,951	21,289
Gross Profit	1,017	1,344	1,070	1,329	2,384
EBITDA	670	837	799	855	1,829
EBITDA Margin%	6%	6.7%	5.6%	5.0%	8.6%
Profit Before Tax	756	858	946	1,143	1,921
Profit After tax	656	717	758	822	1,441
Adjusted EPS	5.9	6.4	6.8	7.4	12.9
Adjusted P/E	51.8	47.4	44.8	41.3	23.6

Source: Company, DevenChoksey Research

Robust Order Wins from Leading U.S. Defense Player Lockheed Martin

- DCX has an order book of INR 30,000 Mn as of 12th Nov'24 vs 19,370 Mn as of 30th June'24. The order book also includes INR 4,603 Mn from Lockheed Martin and also another order worth of INR 3,796 Mn (through Raneal Advanced Systems) from Lockheed Martin for supply of electronic assemblies.
- The massive jump in order book has arrested the concerns around DCX's ability to secure large orders. Additionally, inclusion of key clients such as L&T and Lockheed Martin underscores DCX's ability to deliver high value complicated and critical products for leading defense players.

Margin Pressure Continues to Persist amid Tepid H1

- DCX reported -37%/+42% YoY/QoQ revenue growth during the quarter to INR 1956 Mn in Q2FY25 and the earnings were further aggravated aided by lower gross margin . The gross margins reduced by -485 bps to 3.4% in Q2FY25 vs 8.3% in Q2FY24.
- The EBITDA margin improved sequentially to -1.9% in Q2FY25 vs -3.5% in Q1FY25. However, it delivered 77% QoQ growth in PAT to INR 52 Mn on account of lower finance cost and higher other income.

SHARE HOLDING PATTERN (%)

Particulars	Sep-24 (%)	June-24 (%)	March-24 (%)
Promoters	57.1%	59.8%	62.3%
FIIs	0.8%	1.3%	2.3%
DIIs	7.9%	8.9%	11.2%
Others	34.2%	30.0%	24.2%
Total	100%	100%	100%

^{*}Based on the Today's closing *Note: All the market data is as of Today's closing.

22.3%

Revenue CAGR between FY24 and FY26E



Adj. PAT CAGR between FY24 and FY26E

India Equity Institutional Research

Q2FY25 - Result Update

II 14th Nov 2024

DCX Systems Ltd.

Key Concall Highlights:

NIART Systems JV:

- > The railway JV with ELTA, NIART Systems, has achieved significant milestones, including obtaining licenses for the manufacturing of advanced defense electronics and radar systems.
- NIART's innovations include obstacle detection systems for the railway sector, positioning it as a unique solution in both domestic and international markets.
- Management anticipates NIART will contribute meaningfully to DCX's growth trajectory, with direct orders expected to add to revenue in upcoming quarters.

Order Pipeline:

- DCX reported a strong order book, exceeding INR 3,000 crore, driven by new contracts with global defense giants, including Lockheed Martin.
- The management highlighted robust demand and the ability to secure large-scale, critical defense and aerospace orders, reflecting in DCX's capabilities and execution.

Seasonality:

- > Consistent with previous years, DCX experiences seasonality, with the first two quarters typically being slower due to setup times for procurement, regulatory approvals, and logistical arrangements.
- Management expects a significant pickup in revenue in the latter half of the fiscal year, aligning with the company's historical revenue concentration in Q₃ and Q₄.

Clarity on BOM Guarantee and Raw Material Cost Recovery:

- DCX confirmed the presence of BOM (Bill of Materials) guarantees in most contracts, which allows for the recovery of increased raw material costs.
- > However, due to geopolitical challenges, specifically travel restrictions related to the Israel conflict, some client meetings required to finalize these cost recoveries have been delayed.
- Management anticipates addressing this with clients soon, aiming for cost recovery in the upcoming quarters.

Execution of Order Book:

- > DCX aims to execute approximately 35%-40%% of the current order book within FY25, subject on supply chain timelines and regulatory clearances.
- Management underscored a strong focus on efficient execution, particularly for high-profile orders, to maintain client relationships and secure future contracts.

Outlook and Valuation

DCX has secured strong order book recently from key leading defence players which has given sharp rise to the order book valued at INR 30,000 Mn. At the same time, NIART Systems have garnered positive response from key industry players for the Obstacle detection equipment.

The recent order wins strengthen our confidence in revenue visibility over the near to medium term. However, the ongoing concern around recovering higher raw material costs and sustained margin pressure have led us to revise down our EPS estimates for FY25E/FY26E to INR 7.4/ INR 13 (Previously: INR 11.2/ INR 14.4) respectively. Despite these challenges, we remain confident in DCX's capacity to emerge as a prominent player in the EMS sector, with substantial growth potential in the railway and defense segments. Accordingly, we maintain our P/E multiple of 36x on FY26E EPS and reiterate our BUY rating, setting a target price of INR 466 (previously INR 519).

Source: Company, DevenChoksey Research

▲ KRChoksey

RESEARCH

DCX Systems Ltd.

KEY FINANCIALS

Exhibit 1: Profit & Loss Statement

Particulars (INR Million)	FY22	FY23	FY24	FY25E	FY26E
Revenue from Operations	11,023	12,536	14,236	16,951	21,289
Other Income	221	295	496	553	375
Total Income	11,243	12,832	14,732	17,504	21,664
Cost of Goods Sold	10,006	11,192	13,166	15,622	18,905
Gross Profit	1,017	1,344	1,070	1,329	2,384
Gross Margin	9.2%	10.7%	7.5%	7 . 8%	11.2%
Employee benefit cost	87	105	139	214	276
Other expenses	260	403	132	260	280
Operating expenses	10,353	11,700	13,437	16,097	19,461
EBITDA	670	837	799	855	1,829
EBITDA Margin	6.1%	6.7%	5.6%	5.0%	8.6%
Depreciation Expenses	22	18	51	94	76
Finance cost	113	256	298	170	206
Profit Before Tax	756	858	946	1,143	1,921
PBT Margin	6.2%	6.9%	6.8%	6.6%	6.7%
Tax					
Total Tax	99	141	188	321	480
Tax Rate	13%	16%	20%	28%	25%
Profit After tax	656	717	758	822	1,441
PAT Margin	6.0%	5.7%	5.3%	4.8%	6.8%
Adjusted EPS (INR)	5.9	6.4	6.8	7.4	12.9

Source: Company, DevenChoksey Research

Exhibit 2: Balance Sheet

Particulars (INR Million)	FY22	FY23	FY24	FY25E	FY26E
Assets					
Non Current Assets					
Property Plant and Equipment	108	108	556	537	511
Total Non Current Assets	188	280	660	4,796	4,771
Current Assets					
Inventories	273	2,292	2,035	2,807	3,159
Financial Assets					
i)Investments	-	-	-	-	-
ii)Trade receivable	695	3,195	6,671	6,132	7,509
iii) Cash and cash equivalents	1,885	137	214	-	-
iv)Bank balances other than (ii) above	6,118	5,822	8,194	5,212	5,824
Current Tax Assets (Net)	-	14	-	-	-
Other current Assets	217	433	699	566	633
Total Current Assets	9,238	11,913	17,813	14,716	17,124
Total Assets (INR Million)	9,426	12,193	18,473	19,513	21,895
Equities & Liabilities					
Equity Share Capital	155	193	223	223	223
Reserve & Other Equity	1,021	5,474	11,040	11,988	13,429
Total Equity	1,176	5,667	11,263	12,211	13,651
Non Current Liabilities	-	-	-	-	-
Long Term Borrowings	354	58	202	250	250
Total Non current Liability	365	70	221	275	283
Current Liabilities	-	-	-	-	-
Borrowings	4,672	5,037	2,704	2,880	3,200
Total Trade Payable	965	1,363	3,920	3,277	3,886
Current Tax Liabilities	88	-	23	70	70
Total Current Liability	7,885	6,456	6,990	7,027	7,961
Total Liability	9,426	12,193	18,473	19,513	21,895

Thomson Reuters, Factset and Capital IQ

II 14th Nov 2024



DCX Systems Ltd.

Exhibit 3: Ratios

Profitability Ratios	FY22	FY23	FY24	FY25E	FY26E
Gross Margin%	9.2%	10.7%	7.5%	7.8%	11.2%
Operating Margin%	6.1%	6.7%	5.6%	5.0%	8.6%
PAT margin%	6.0%	5.7%	5.3%	4.8%	6.8%
Return Ratios	FY22	FY23	FY24	FY25E	FY26E
ROCE%	21.6%	13.1%	10.0%	8.9%	13.1%
ROE%	79.8%	20.9%	9.0%	7.0%	11.1%
ROA%	7.6%	6.6%	4.9%	4.3%	7.0%
Working Capital & Turnover Ratios	FY22	FY23	FY24	FY25E	FY26E
Debtor Days	23	93	171	132	129
Inventory Days	10	75	56	66	61
Creditor Days	35	44	109	77	75
Working Capital Days	-2	123	119	121	115
Debtor Turnover	16	4	2	3	3
Inventory Turnover	37	5	6	6	6
Paybles Turnover	10	8	3	5	5
Coverage Ratio	FY22	FY23	FY24	FY25E	FY26E
Debt to Equity (x)	4.3	0.9	0.3	0.3	0.3
Interest Coverage (x)	7.7	4.3	4.2	7.7	10.3
Valuation Ratios	FY22	FY23	FY24	FY25E	FY26E
Adjusted EPS	5.9	6.4	6.8	7.4	12.9
Adjusted Book Value	10.6	50.9	101.1	109.6	122.6
Adjusted Price to Earnings (x)	51.8	47-4	44.8	41.3	23.6
Adjusted Price to Book Value (x)	28.9	6.0	3.0	2.8	2.5
EV/EBITDA (x)	49.1	39.7	35.9	37.3	17.3

Source: Company, DevenChoksey Research

Exhibit 3: Cash Flow Statement

Particulars (INR Million)	FY22	FY23	FY24	FY25E	FY26E
Net Cash Flow from Operation	-1,340	-5,902	44	471	175
Net Cash Flow from Investing Activities	208	219	-13	-3,721	323
Net Cashflow from Financing activities	3,642	3,638	2,418	54	114
Opening cash balance	5,493	8,003	5,958	8,408	5,212
Closing Cash	8,003	5,958	8,408	5,212	5,824

Source: Company, DevenChoksey Research

RESEARCH

DCX Systems Ltd.

DCX Systems Ltd.							
Date	CMP (INR)	TP (INR)	Recommendation				
14-Nov-24	303	466	BUY				
16-Aug-24	331	519	BUY				
22-May-24	331	519	BUY				
09-Feb-24	350	519	BUY				

Rating Legend (Expected over a 12-month period)				
Our Rating Upside				
Buy	More than 15%			
Accumulate	5% – 15%			
Hold	o – 5%			
Reduce	-5% – o			
Sell	Less than - 5%			

ANALYST CERTIFICATION:

I, Dipak Saha (MBA, Finance), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000001295. It is also registered as a Depository Participant with CDSL, CDSL Registration No IN-DP-425-2015

KRChoksey Shares & Securities Pvt Ltd. and DRChoksey Finserv Private Ltd. (Demerged entity from KRChoksey Shares & Securities Limited) are regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of Research Analysts including preparing and distribution of Research Reports. This research report is prepared and distributed by DRChoksey Finserv Private Ltd in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INHo00001126. It may be further notified that KRCSSPL carries on the activity of preparation as well as distribution of reports in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INHO00001295.

Deven Choksey Research is a brand name of DRChoksey Finsery Private Limited. The information and opinions in this report are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavour to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension follows applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report any not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. RRCSSPL accepts no liabilities whatsoever for investing in of the use of this report. Past performance is not necessarily a guide to future performance, investors are advised to see Riski Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these mate aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities. KRCSSPL prohibits its associate, analysts,

persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by analyst.

It is confirmed that, I, Dipak Saha Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based

on any specific brokerage service transactions.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months

NRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services of services.

KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict or preparation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that, Dipak Saha, Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.

It is confirmed that, Dipak Saha, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

RKCSSPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com

In case of any grievances, please write to grievance@krchoksey.com Visit us at www.krchoksey.com KRChoksey Shares and Securities Pvt. Ltd. CIN-U67120MH1997PTC108958

CIN-UD/LOWINIPSY/TI-CLOUGES Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001. Phone: 91-22-6633 5000; Fax: 91-22-6633 8060 Corporate Office: 701-702, DLH Plaza, Opp Shoppers Stop, S V Road, Andheri (W), Mumbai 400 058

Phone: 91-22-66535000

Compliance Officer: Varsha Shinde Email: varsha.shinde@krchoksey.com

KRChoksey Research